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The aim of this study was to assess whether a combination of gemcitabine (GEM) with either paclitaxel (PTX) or vinorelbine (VNR)
could be more effective than GEM or PTX alone in elderly or unfit advanced non-small-cell lung cancer (NSCLC) patients. A total of
264 NSCLC patients aged 470 years with ECOG performance status (PS)p2, or younger with PS¼2, were randomly treated with:
GEM 1200mgm
 2 on days 1, 8 and 15 every 28 days; PTX 100mgm
 2 on days 1, 8 and 15 every 28 days; GEM 1000mgm
 2 plus
PTX 80mgm
 2 (GT) on days 1 and 8 every 21 days; GEM 1000mgm
 2 plus VNR 25mgm
 2 (GV) on days 1 and 8 every 21 days.
In all arms, an intra-patients dose escalation was applied over the first three courses, provided that no toxicity of WHO grade X2
had previously occurred. At present time, 217 (82%) patients had died. The median (months) and 1-year survival probability were 5.1
and 29% for GEM, 6.4 and 25% for PTX, 9.2 and 44% for GT, and 9.7 and 32% for GV. Multivariate analysis showed that PSp1
(hazard ratio (HR)¼0.67; 95% CI 0.51–0.90), and doublet treatments (HR¼0.76; 95% CI 0.59–0.99) were significantly associated
with longer survival. Doublets produced no more toxicity than single agents. GT should be considered a reference regimen for elderly
NSCLC patients with PSp1.
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The standard approach for advanced non-small-cell lung cancer
(NSCLC) is still a matter of debate. Indeed, there is a general
consensus that cisplatin-based chemotherapy may produce a short
but significant survival prolongation and improve the quality of
life of patients in comparison with best supportive care alone (Non
Small Cell Lung Cancer Collaborative Group, 1995; Cullen et al,
1999). Moreover, the Eastern Cooperative Oncology Group
(ECOG) trial E1594 has recently shown that platinum doublets
(cisplatin plus gemcitabine, cisplatin plus paclitaxel, carboplatin
plus paclitaxel, or cisplatin plus docetaxel) have equivalent efficacy
while differing in cost, toxicity and convenience (Schiller et al,
2002). However, there is still a diffuse concern about the
tolerability of cisplatin in elderly and/or unfit patients (Earle
et al, 2001; Bunn and Lilenbaum, 2003; Hennessy et al, 2003). As a
matter of fact, the perceived rate of unacceptable toxicity among
patients with poor performance status (PS) induced the disconti-
nuation of their accrual in the above-mentioned ECOG E1594
study (Sweeney et al, 2001), and retrospective analyses on
randomised trials have shown that PS 2 patients have no survival
gain from chemotherapy (Billingham and Cullen, 2001; Soria et al,
2001).
As for elderly patients, two different approaches have recently
emerged in literature. One of these has been to perform age-
specific retrospective analyses on patients treated in randomised
trials evaluating cisplatin-based doublets. Accordingly, several
authors have recently reported neither substantial difference in
survival, nor greater toxicity, for elderly patients treated with these
regimens (Kelly et al, 2001; Rocha Lima et al, 2002; Hensing et al,
2003; Langer et al, 2003). However, these findings have the clear
drawback of being extrapolated from studies carried out for
different purposes.
A different approach for addressing this problem has been to
explore in prospective trials the benefit of non-cisplatin-based
treatments. The first one of these studies has been the ELVIS trial
(Elderly Lung cancer Vinorelbine Italian Study Group, 1999),
which showed an advantage in the median survival time (MST) (28
vs 21 weeks) for elderly patients receiving single agent vinorelbine
as compared to those treated with supportive care alone. Single
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lagent paclitaxel was also demonstrated to produce a 2-month
longer MST (6.8 vs 4.8 months) in comparison with supportive
care in a randomised trial with no upper limit of age for accrual
(Ranson, 2000), and this drug appeared highly attractive for
treating elderly patients, in view of the increasing evidence that a
weekly schedule may improve its toxicity profile (Alberola et al,
2002). Furthermore, retrospective (Martin et al, 1997; Shepherd
et al, 1997) and prospective studies (Altavilla et al, 2000; Anderson
et al, 2000; Ricci et al, 2000) have also supported the use of
gemcitabine in elderly NSCLC patients, given its good tolerability
and activity regardless of age.
A further step ahead on this issue was made by the Southern
Italy Cooperative Oncology Group (SICOG), which demonstrated
that a combination of gemcitabine plus vinorelbine fared
better than vinorelbine alone in elderly patients, obtaining a
MST of 29 vs 18 weeks, and delaying the symptom and quality of
life deterioration (Frasci et al, 2000). Moreover, this study
highlighted that a high Charlson score (X3) was associated
with the worst survival, suggesting that a comprehensive geriatric
assessment, specifically looking at the type and number of
the comorbidities, was mandatory in order to select the patients
who may take advantage from a potentially active treatment
(Frasci, 2002).
In the meantime, other investigators have explored the efficacy
of original schedules of gemcitabine plus paclitaxel in NSCLC
patients. For instance, Spanish investigators assessed a biweekly
regimen with gemcitabine 2000mgm
 2 plus paclitaxel
150mgm
 2, obtaining a 32% response rate (RR), and a 9.9
months MST, in the absence of grade X3 myelotoxicity (Isla et al,
2001). Hirsh et al (2003) administered gemcitabine 1000mgm
 2
plus paclitaxel 100mgm
 2, both on days 1 and 8 every 3 weeks,
reporting a 55% RR and an MST of 9.8 months, with negligible
myelosuppression. Therefore, the fractionated administration of
paclitaxel and gemcitabine on the same days apparently increased
the therapeutic index of the combination, supporting its use in
elderly patients.
With these premises in mind, we decided to set up a new trial
(SICOG 9909) restricted to elderly or unfit NSCLC patients with a
Charlson score p4. The primary aim of this trial was to assess
whether the combination of gemcitabine plus either vinorelbine or
paclitaxel could prolong the survival of patients in comparison
with gemcitabine or paclitaxel alone. Secondary end points were
time to treatment failure, response rate and toxicity. Furthermore,
because at that time there was no agreement on the optimal dosage
of these compounds for managing aged patients, and given the
unpredictable tolerability of chemotherapy in elderly people, we
used an individual dose optimisation (Frasci et al, 1998), starting
treatment with the minimum active dose of each cytotoxic drug,
applying a substantial dose reduction in the presence of
haematologic toxicity as in our previous trial (Frasci et al, 2000),
and assessing the feasibility of an intra-patient dose escalation only
in the absence of a relevant toxicity on previous cycle.
PATIENTS AND METHODS
Patients selection
The main eligibility criteria for this study were: histologically or
cytologically proven diagnosis of NSCLC; age 470 years associated
with an ECOG PS p2, or age p70 years coupled with a PS 2; stage
IIIB (not amenable to local treatment) or stage IV of disease;
presence of measurable lesion(s); Charlson score no greater than 4;
normal bone marrow reserve (neutrophil count X2000ml
 1,
platelet count X100000ml
 1, haemoglobin concentration
X10gdl
 1); adequate liver (bilirubin level o2 the upper normal
limit (UNL), AST and ALT o3 UNL) and renal function
(creatinine clearance X60mlmin
 1). Exclusion criteria were:
presence of brain metastasis, uncontrolled metabolic or infectious
diseases, presence of severe cardiac arrhythmia or heart failure,
previous exposure to chemotherapy or radiotherapy, and previous
diagnosis of malignant tumour within the last 5 years. The study
protocol was approved by the Independent Ethical Committee of
the National Tumour Institute of Naples, and written informed
consent was required from each patient before registration.
Within a month before inclusion, all patients were submitted to
a careful staging work-up, including history, physical examination,
chest X-ray, ECG, computed tomography (CT) scan of thorax and
upper abdomen, and bone radionuclide scan. Additional tests were
performed only when clinically indicated. Within a week before
registration, a full biochemistry profile, and a blood cell count with
differential, were performed. Biochemistry was repeated at the
start of each subsequent cycle, while blood cell count was
performed weekly.
Stratification, randomisation, and treatment
Patients were registered by fax at the coordinating centre. After
verifying the eligibility criteria, patients were stratified according
to stage (IIIB vs IV), PS (0–1 vs 2), and Charlson score (0–2 vs 3–
4), and allocated using a computer-generated random list into one
of four arms: gemcitabine (GEM), paclitaxel (PTX), gemcitabine
plus paclitaxel (GT), or gemcitabine plus vinorelbine (GV). In all
arms of the trial, at least three cycles were planned before the
assessment of activity, and further treatment was administered
up to a maximum of six cycles only if at least a disease control
was demonstrated. In the absence of World Health Organiza-
tion (WHO) grade X2 toxicity on previous cycle, an intra-patient
dose escalation over the first three cycles was planned in all
arms of the trial, and the dosage reached in the third cycle was
used thereafter.
In the GEM arm, the first cycle consisted of gemcitabine
1200mgm
 2 infused intravenously (i.v.) over 30min on days 1, 8
and 15, recycling every 4 weeks. Gemcitabine could be increased to
1400mgm
 2 on the second cycle, and to 1600mgm
 2 on the third
cycle. In the PTX arm, initial dose was 100mgm
 2 infused i.v. over
1h on days 1, 8 and 15, recycling every 4 weeks. PTX could be
increased to 120mgm
 2 on the second cycle, and to 140mgm
 2
on the third cycle. In the GT arm, paclitaxel 80mgm
 2 (over 1h),
followed by gemcitabine 1000mgm
 2 (over 30min), was adminis-
tered i.v. on days 1 and 8, recycling every 3 weeks. Gemcitabine
could be increased to 1200mgm
 2 on the second cycle, while
paclitaxel could reach 100mgm
 2 on the third cycle. In the GV
arm, gemcitabine 1000mgm
 2 (in 30min), and vinorelbine
25mgm
 2 (in 15min) were given i.v. on days 1 and 8, recycling
every 3 weeks; gemcitabine could be increased to 1200mgm
 2 on
the second cycle, while vinorelbine could be increased to
30mgm
 2 on the third cycle.
In each arm of the trial, chemotherapy was administered in the
presence of neutrophil count X1500dl
 1, platelet count
X100000dl
 1 and after complete recovery from previous non-
haematologic toxicity. In the presence of neutrophil count o1500
but X1000dl
 1 and/or platelet count o100000 but X75000dl
 1,
a 50% dose reduction was applied for each drug. If lower values
occurred on the initial day of each cycle, chemotherapy was
postponed for a week, while doses were omitted if they did occur
on day 8 or 15. Anti-emetic treatment and prevention of allergic
reactions were provided according to standard guidelines.
Supportive care was not defined in the study protocol, and it
was left to investigator’s choice. Treatment was discontinued in
the case of documented tumour progression after three cycles,
or earlier in the case of severe toxicity, deterioration of
clinical condition, or withdrawal of patient’s consent. Adminis-
tration of palliative radiotherapy was left to the discretion of the
attending physician. After discontinuation of study treatment, no
further cytotoxic treatment was administered. Patients received
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lsymptomatic treatment, and were followed every month for the
assessment of disease status and survival.
Evaluation of toxicity and response
Toxicity was assessed after each cycle of treatment and scored
according to WHO criteria (Miller et al, 1981). The worst degree of
toxicity experienced throughout the treatment was recorded for
each patient. Activity was defined by repeating a complete
diagnostic work-up after three cycles, and at the end of therapy,
and the best patient’s response was recorded for the analysis.
Responses were classified according to WHO criteria (Miller et al,
1981). Early treatment discontinuation or death for any cause were
considered as treatment failures. Duration of complete response
was measured from the date it was first documented, while
duration of partial response was calculated from the date of
randomisation to the date of progression or death, whichever
occurred first.
Evaluation of survival
Survival of patients was calculated from the date they were
randomised to the date of death or last follow-up. All patients
treated as allocated as well as patients not treated according to
random assignment were included in this analysis according to the
intent-to-treat principle. Failure-free survival was calculated for
each patient from the date of randomisation to the date of
progression or failure.
Statistical analysis and sample size
Proportions were calculated with 95% exact confidence interval
(95% CI) and compared using the Fisher’s exact test. Actuarial
survival and failure-free survival curves were generated using the
Kaplan and Meier method (Kaplan and Meier, 1958) and compared
using a two-sided log-rank test (Mantel, 1996). All statistical
analyses were performed using the software SPSS software
package, version 8.0 (SPSS Inc., Chicago, IL, USA).
The sample size was defined assuming from previous experience
that both single-agent treatments could obtain a MST of 5 months.
To detect an improvement to 7.5 months with a doublet regimen, a
total of 257 events were required, giving a 90% power to obtain a
P-value o0.05 at the log-rank test. Therefore, a total sample size of
130 patients per arm was planned. The enrolment started in May
1999, and we anticipated to complete the case accrual in about 4
years. However, in March 2003 we decided to close the
recruitment, in consideration of the slower than anticipated
accrual, and on the basis of some ethical concern raised by a
recently published trial in elderly patients, in which no survival
benefit derived for the combination of gemcitabine plus vinor-
elbine over gemcitabine alone (Gridelli et al, 2003). Participating
investigators were required to perform an ad hoc analysis of
survival for patients enrolled until that date, allowing for a 6-
month minimum follow-up after the last patient had been
recruited. A multivariate analysis with a backward selection
procedure (Cox, 1972) was also applied to evaluate the best factors
independently affecting survival, including as discrete covariates:
age of patients (more or less than 70 years), performance status
(0–1 or 2), previous weight loss (yes or not), Charlson score (0–2
or 3–4), histologic subtype (squamous carcinoma, adenocarcino-
ma, or other subtypes), stage of disease (IIIB or IV) and treatment
(single agent or doublet).
RESULTS
Patient characteristics
From May 1999 to March 2003, 271 patients were registered into
this study. However, seven patients were not randomised because
of wrong histology (one patient), or no available baseline
information about requirements of eligibility (six patients). In
all, 264 patients were randomly allocated to one of four arms
(Figure 1). A total of 16 patients did not receive treatment as
allocated, because of withdrawal of patient’s consent (five cases),
or because of attending physician’s decision (11 cases): these
patients were not considered in the analysis of activity and toxicity,
but were included in the survival analysis.
As detailed in Table 1, most patients (89%) were males. In all,
220 (83%) patients were older than 70 years. Among these, 93
(35%) patients were aged X75 years, and 14 (5%) were aged X80
years. However, 44 (17%) patients aged p70 years were also
enrolled because of their poor PS. Regardless of age, 77 (29%)
patients had an ECOG PS 2. Squamous cell carcinoma accounted
for 48% of all diagnoses, followed by adenocarcinoma (27%). In
total, 98 (37%) patients were classified in stage IIIB, and 166 (63%)
patients were in stage IV; 41 (25%) of these patients had more than
one metastatic site of disease. A recent weight loss was registered
in 91 (34%) patients. In 87 (33%) patients no associated diseases
were recorded, while 161 (61%) patients had a Charlson score 1
Registered 
(n = 271)
Not eligible
(n = 7)
Randomised 
(n = 264)
Allocated to GEM 
(n = 68) 
Not treated (n = 6) 
Allocated to PTX 
(n = 63)
Not treated (n = 2) Not treated (n = 3)
Allocated to GV
(n = 68) 
Allocated to GT 
(n = 65) 
Analysed (n = 68) Analysed (n = 63) Analysed (n = 68)
56 deaths; 12 alive
Follow-up:
 < 6 months (n = 5)  
>12 months (n = 4)
57 deaths; 6 alive
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Follow-up:
 < 6 months (n = 3)  
6 −12 months (n = 2) 6 −12 months (n = 3)
>12 months (n = 1)
54 deaths; 14 alive
Follow-up:
 < 6 months (n = 4)  
6 −12 months (n = 3)
>12 months (n = 7)
52 deaths; 13 alive
Follow-up:
 < 6 months (n = 4)  
6 −12 months (n = 2)
>12 months (n = 7)
Not treated (n = 5)
Analysed (n = 65)
Figure 1 Consolidation of Standards for Reporting Trials (CONSORT) flow chart of the study.
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lor 2, and 16 (6%) patients had a score X3 (Table 2). All
pre-treatment characteristics resulted well balanced across the four
arms of the trials.
Survival and failure-free survival
Survival was the main end point of this study, and all 264 eligible
patients were included in this analysis according to intent-to-treat
principle. By September 30, 2003, the median potential follow-up
for the whole series was 33 (range, 6–52) months, with no
difference between arms of treatment. At that time, 219 (83%)
patients had died, and MST for the whole series was 7.5 (95% CI,
5.9–9.1) months. Early death (within 60 days from randomisation)
occurred in 14 (21%) patients of the GEM arm, in eight (13%)
patients of the PTX arm, in nine (14%) patients of the GT arm and
in nine (13%) patients of the GV arm. Both doublets produced a
longer survival than single agents (Figure 2). Indeed, MST and 1-
year survival rate (1-year SR) were 9.2 months and 44% for
patients treated with GT, 9.7 months and 32% for patients treated
with GV, 6.4 months and 25% for patients treated with PTX, and
5.1 and 29% for patients treated with GEM. Difference between GT
and PTX approached the significance level (P value¼0.051), while
difference between GV and GEM was not significant.
The pooled comparison of survival of patients treated with
either GEM or PTX vs patients treated with either GV or GT
showed a significant difference in favour of doublet regimens
(Figure 3). Indeed, the MST and 1-year SR were 5.7 (95% CI, 3.9–
7.5) months and 28% for single-agent treatments, and 9.2 (95% CI,
7.6–10.8) months and 39% for the combinations (P-value¼0.028).
The multivariate analysis showed that only PS and treatment
independently affected the survival of patients. Indeed, the hazard
ratio of death was 0.67 (95% CI, 0.51–0.90) for patients with
performance status 0 or 1 as compared to patients with poorer
performance status (P-value¼0.0068), and it was 0.76 (95% CI,
0.59–0.99) for patients treated with a doublet compared to patients
treated with a single agent (P-value¼0.0486).
The failure-free survival curves are plotted in Figure 4. Also in
this case, both doublets were associated with a longer failure-free
survival than each single-agent regimen. The median failure-free
interval (in months) was 4. 5 for patients treated with GT, and
4.1 for patients treated with GV, while it was 3.7 for PTX, and
3.3 for GEM. However, these differences did not reach a
significant level.
Table 2 Type of comorbidities, and Charlson score, according to arms
of treatment
GEM PTX GV GT
Associated diseases No. % No. % No. % No. %
Myocardial infarction 2 3 3 5 1 4 3 5
Chronic cardiac failure 5 7 1 1 2 3 2 3
Peripheral vascular 5 7 8 12 3 4 8 12
Cerebral vascular 7 10 3 5 4 6 4 6
Dementia 1 1 0 0 0 0 0 0
Chronic bronchopneumonia 20 29 21 32 19 28 19 29
Connectivitis 1 1 0 0 1 4 2 3
Peptic ulcer 2 3 3 5 2 3 5 8
Chronic hepatitis 1 1 2 3 2 3 7 11
Diabetes 3 4 6 9 4 6 5 8
None 23 34 20 32 21 31 23 35
Charlson score
0 2 33 42 03 22 13 12 33 5
1 – 2 4 26 23 65 74 36 34 06 2
3 – 4 347 1 14623
GEM¼gemcitabine, PTX¼paclitaxel, GV¼gemcitabine plus vinorelbine,
GT¼gemcitabine plus paclitaxel.
Table 1 Characteristics of patients enrolled in the SICOG trial 9909 according to the arm of treatment
GEM PTX GV GT
Characteristics No. (%) No. (%) No. (%) No. (%)
Number of patients 68 (100) 63 (100) 68 (100) 65 (100)
Males 57 (84) 57 (90) 63 (93) 59 (91)
Females 11 (16) 6 (10) 5 (7) 6 (9)
Median age (range) 75 (49–86) 72 (50–81) 72 (42–82) 73 (53–83)
Agep70 years 9 (13) 13 (21) 13 (19) 9 (14)
Weigh loss 45% 23 (34) 31 (49) 18 (27) 19 (29)
PS 0–1 49 (72) 41 (65) 47 (69) 50 (77)
PS 2 19 (28) 22 (35) 21 (31) 15 (23)
Stage III 24 (35) 16 (25) 28 (41) 25 (38)
Stage IV 44 (65) 47 (75) 40 (59) 40 (62)
2+ metastatic sites 13 (30) 10 (21) 10 (26) 8 (21)
Squamous carcinoma 27 (40) 33 (52) 34 (50) 33 (51)
Adenocarcinoma 24 (35) 18 (29) 13 (19) 16 (25)
Large-cell carcinoma 3 (4) 4 (6) 10 (15) 3 (4)
Unclassified 14 (21) 8 (13) 11 (16) 13 (20)
GEM¼gemcitabine, PTX¼paclitaxel, GV¼gemcitabine plus vinorelbine, GT¼gemcitabine plus paclitaxel.
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ARM Pts Events  median  95%  CI 
GEM 68 2.2 − 8.0 
PTX 63 4.4 − 8.4 
GV 68 7.9 − 11.5
GT 65
56 5.1
57 6.4
54 9.7
9.2 52 4.8 − 13.6
Months
Figure 2 Actuarial survival curves of patients according to the four arms
of the trial: GEM arm (black diamond), PTX arm (white diamond), GV arm
(open circle), GT arm (close circle). The differences did not reach a
significant P-value.
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In all arms, median number of administered cycles was three
(range, 1–6) per patient. Early treatment discontinuation, due to
rapid deterioration of clinical conditions, occurred in similar
proportions of patients in all arms of the study (Table 3). Early
withdrawal was significantly associated with baseline PS of
patients. Indeed, 35 (45%) of 77 patients with PS 2 received less
than three courses as compared to 42 (24%) of 172 patients with PS
0o r1( P-value¼0.0009).
In GEM arm, a dose escalation was performed on the second
cycle in 24 (48%) patients, and the mean administered dose was
1286mgm
 2. On the third cycle, gemcitabine was further escalated
in 14 (39%) patients, and the mean dose was 1371mgm
 2. Dose
reductions or omissions occurred in 37% of patients on the first
cycle, in 32% of patients on the second cycle and in 39% of patients
on the third cycle. First PTX dose escalation was performed in 26
(55%) patients, and the mean dose on the second cycle was
111mgm
 2. On the third cycle, an escalation was applied in 16
(43%) patients, and the mean dose given was 119mgm
 2.
Reduction or omissions were required in 18% of patients on the
first cycle, in 15% of patients on the second cycle and in 19% of
patients on the third cycle. In the GT arm, gemcitabine was
increased in 26 (51%) patients, and its mean dose on the second
cycle was 1094mgm
 2, while paclitaxel was increased in 24 (50%)
patients, and its mean dose on the third cycle was 89mgm
 2. Dose
reductions occurred in 23% of patients on the first cycle, in 22% of
patients on the second cycle and in 13% of patients on the third
cycle. In the GV arm, gemcitabine was escalated in 21 (40%)
patients, and its mean dose on the second cycle was 1080mgm
 2,
while vinorelbine was increased in 12 (24%) patients on the third
cycle, and its mean dose was 26mgm
 2. Dose omissions occurred
in 15% of patients on the first cycle, in 11% of patients on the
second cycle and in 10% of patients on the third cycle.
Activity
In all, 11 patients showed a partial response in GEM arm, for an RR
of 18% (95% CI, 9–30%); eight patients obtained a partial
response in PTX arm, giving an RR of 13% (95% CI, 6–24%); 19
partial responses were achieved with GT regimen, giving an RR of
32% (95% CI, 20–45%); one complete plus 14 partial responses
were registered among patients treated with GV, giving an RR of
23% (95% CI, 13–35%). RRs in metastatic patients were 18, 15, 25
and 25%, respectively, for the GEM, PTX, GT and GV regimens.
Patients with better PS had a higher RR than patients with poor PS:
RR was 17 vs 15% in the GEM arm, 17 vs 5% in PTX arm, 28% vs
no response in the GT arm and 38 vs 9.5% in the GV arm.
Conversely, no substantial difference of activity was apparent
among patients age X75 years: RR was 15 and 5% in the GEM
and PTX arms, respectively, while it resulted 29% in both
combination arms.
The overall activity of GT resulted significantly greater than that
of PTX (P-value¼0.013), while the comparison of GV vs either
single agent did not reach a level of significance. Noteworthy, the
proportion of patients achieving a control of tumour growth
(major response or stabilisation) was 37% in the GEM arm, 34% in
the PTX arm, 60% in the GT arm and 53% in the GV arm. In this
respect, both doublets resulted significantly more active than
single agents.
Considering the patients treated with at least three cycles, a
higher proportion of responses occurred among patients able to
tolerate a dose escalation of both drugs in the GT or GV arm, as
opposed to those in whom escalation was limited to gemcitabine,
or not feasible at all: responders were 12 out of 24 (50%) patients
in the GT arm, and seven out of 12 (58%) patients in the GV arm,
as opposed to seven out of 24 (29%) and eight out of 40 (20%)
patients, respectively. Conversely, no substantial difference in RR
according to drug escalation was observed in GEM or PTX arm.
Responders were four out of 14 (29%) and four out of 16 (25%)
patients, respectively, receiving a full dose escalation over three
cycles, and seven out of 22 (32%) and four out of 21 (19%)
patients, respectively, with partial or no dose escalation.
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Single agents 131 3.9 – 7.5 
Doublets 133
113 5.7
9.2 106 7.6 – 10.8 
Months
Figure 3 Actuarial survival curves of patients treated with either single
agent (thin line) or with either doublet (thick line). The difference was
significant at the log-rank test (P¼0.028).
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ARM Pts Events  median  95%  CI 
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Figure 4 Actuarial failure-free survival curves of patients according to
the four arms of the trial: GEM arm (black diamond), PTX arm (white
diamond), GV arm (white circle), or GT arm (black circle). The differences
did not reach a significant P-value.
Table 3 Administered cycles according to arms of treatment
GEM PTX GV GT
Treatment No. % No. % No. % No. %
Not treated patients 6 9 2 3 3 4 5 8
Treated patients 62 91 61 97 66 96 60 92
Total cycles 176 175 233 219
Median cycles/patient 3333
X2 cycles 50 81 47 77 53 80 51 85
X3 cycles 36 58 37 61 52 79 48 80
X4 cycles 13 21 13 21 24 36 23 38
X5 cycles 9 15 10 16 22 33 20 33
X6 cycles 7 11 7 11 15 23 14 23
GEM¼gemcitabine, PTX¼paclitaxel, GV¼gemcitabine plus vinorelbine,
GT¼gemcitabine plus paclitaxel.
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lDuration of major responses ranged from 4.6 to 15.0 months, with
no substantial differencesacross the fourarms ofthe study (Table 4).
Toxicity
No toxic deaths were registered in this trial. Severe neutropenia
occasionally occurred, and few patients in each arm experienced
febrile neutropenia (Table 5). Severe thrombocytopenia occurred
in six patients (three cases of grade 4) of the GEM arm, in two
patients (one case of grade 4) of the GV arm, and in four patients
(two cases of grade 4) of the GT arm. However, no episodes of
bleeding occurred, nor platelet transfusions were required.
Anaemia of any grade affected a similar proportion of patients
in GEM (25%), GT (25%) and GV (26%) arms, while it was very
rare in the PTX arm (12% of patients). Furthermore, we would
remark that, among patients treated with GEM alone, severe
anaemia occurred more frequently in patients aged X75 years
(13%) than in younger ones (7%), while no difference according to
age grouping was seen in the other arms of the study. Packed red
cell transfusions were given during treatment to four patients of
the GEM arm, and to one patient each of the GV and GT arms.
Nonhaematologic toxicity was quite mild, and few episodes of
grade X3 toxicity of any type were reported (Table 6). Mild–
moderate stomatitis occurred in seven (12%) patients treated in
the PTX arm, and in five (9%) patients treated in the GT arm.
Neurologic toxicity of any grade was seen in five patients (10%)
treated with GV, in seven patients (13%) treated with GT, in four
patients (7%) patients treated with PTX and in two patients (4%)
treated with GEM. However, it should be remembered that twice as
many patients in GT or GV arm received six cycles as compared to
the GEM or PTX arm.
DISCUSSION
The aim of this study was to ascertain whether a regimen including
gemcitabine plus either vinorelbine or paclitaxel could prolong the
survival of elderly patients with locally advanced or metastatic
NSCLC patients in comparison with a single-agent treatment with
gemcitabine or paclitaxel. We selected these doublets on the
ground of their exciting activity demonstrated in our own previous
experience (Frasci et al, 2000; Lorusso et al, 2000; Frasci, 2002), as
well as in other studies (Isla et al, 2001; Hirsh et al, 2003), while
paclitaxel and gemcitabine were identified as single agents to be
challenged on the basis of several retrospective and prospective
reports about their efficacy and tolerability in NSCLC patients.
The results reported here showed that both doublets produced a
longer survival than either single agent. Failure-free survival
analysis also showed an advantage for patients treated with either
GV or GT in comparison with patients treated with either
gemcitabine or paclitaxel. The higher activity of doublets in
comparison with single agents was confirmed by the greater
response and disease control rates. However, differences in
survival did not reach a significance level. As we had decided to
prematurely close the case accrual before the planned sample size
Table 4 Summary of activity according to arms of treatment
Outcome GEM PTX GV GT
Response rate 18 13 23 32
95% CI 9–30 6–24 13–35 20–45
Disease control rate 37 34 53 60
95% CI 25–50 23–48 40–65 45–71
Duration of responses
Median (months) 6.8 6.6 7.6 6.5
Range 4.6–15 4.2–9.0 5.0–10.2 5.8–8.2
Survival
Median (months) 5.1 6.4 9.7 9.2
95% CI 2.2–8.0 4.4–8.4 7.9–11.5 4.8–13.6
1-year survival probability 29 25 32 44
95% CI 17–41 13–37 20–44 32–56
2-year survival probability 8 8 14 11
95% CI 1–16 1–16 4–24 1–21
Failure-free survival
Median (months) 3.3 3.7 4.1 4.5
95% CI 2.6–4.0 2.9–4.5 2.9–5.3 2.8–5.6
6-month probability 33 31 33 36
GEM¼gemcitabine, PTX¼paclitaxel, GV¼gemcitabine plus vinorelbine,
GT¼gemcitabine plus paclitaxel.
Table 5 Acute haematologic toxicity according to arm of treatment
GEM (59) PTX (60) GV (61) GT (57)
WHO toxicity
Arm
(patients)
No. % No. % No. % No. %
Neutropenia G1 10 17 7 12 5 8 9 16
G 2 3 5 8 1 31 11 8 9 1 6
G 3 7 1 2 3 558 3 5
G 4 35 2 346 2 3
Febrile neutropenia 2 3 2 3 3 5 1 2
Thrombocytopenia G1 4 7 2 3 7 11 7 12
G 2 61 00 0 5 861 1
G 3 35 0 012 2 3
G 4 35 0 012 2 3
Anaemia G1 7 12 5 8 7 11 6 11
G2 2 3 1 2 6 10 7 12
G 3 58 1 235 2 2
G 4 12 0 000 0 0
GEM¼gemcitabine, PTX¼paclitaxel, GV¼gemcitabine plus vinorelbine,
GT¼gemcitabine plus paclitaxel.
Table 6 Acute nonhaematologic toxicity according to the arm of
treatment
GEM (59) PTX (59) GV (61) GT (57)
WHO toxicity
Arm
(Patients)
No. % No. % No. % No. %
Vomiting G1–2 9 15 14 24 14 23 10 18
G 3 2 3002324
Diarrhoea G1–2 2 4 58476 1 1
G 3 – 4 0 0120012
Stomatitis G1–2 2 3 7 12 5859
G 3 – 4 1 2001300
Neurologic G1–2 1 2 47476 1 1
G 3 – 4 1 2001312
Renal G1–2 2 4 002324
G 3 1 2000000
Hepatic G1–2 1 2 004735
G 3 0 0000012
Alopecia G1–2 8 14 12 20 17 28 11 19
G 3 0 047007 1 2
Allergic G1–2 3 5 354735
Constipation G1–2 2 4 234713
GEM¼gemcitabine, PTX¼paclitaxel, GV¼gemcitabine plus vinorelbine,
GT¼gemcitabine plus paclitaxel.
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lof patients had been reached, we may speculate that these findings
may be due to the low power of the test performed on a small
patient population. For this reason, and given the similar outcome
of patients treated with either single agent, as well as of patients
treated with either doublet, we performed a pooled analysis, which
showed a significant difference in favour of doublets. Furthermore,
multivariate analysis of factors independently affecting the
probability of survival revealed that only a poor performance
status and a single-agent treatment were significantly associated
with a shorter outcome.
It is worth noting that the actual MST of patients treated with
either single agent was very close to that assumed in the design of
the study, while patients treated with doublets fared even better
than hypothesised. However, we have to underline that these
results were obtained in a carefully selected patient population, as
reflected by the lower than anticipated accrual rate. Indeed, while
the proportion of patients with poor PS was similar in this (29%)
and in our previous trial (24%) (Frasci et al, 2000), patients with
brain metastases were excluded from the present trial. In addition,
the present series was affected by less comorbidities. The adverse
impact of the number of associated diseases, summarised by the
Charlson score, on survival of elderly NSCLC patients was already
demonstrated in our previous study (Frasci, 2002), and it has been
confirmed in the present trial. Indeed, MST for patients with a
Charlson score X3 was 16 weeks in our previous study, and 4.0
months in the present trial, while it was 23 weeks and 7.6 months,
respectively, for patients with a lower score. However, patients
with a Charlson score X3 were 18% in the previous trial and only
6% in the present series. These differences could partially explain
the better than anticipated outcome observed in patients treated
with doublets. Indeed, it may be argued that patients with a
favourable prognosis could have benefited more from an active
treatment than patients for whom life expectancy was already
heavily compromised by their comorbidities.
In contrast to the present study, the Multicenter Italian Lung
cancer in Elderly Study (MILES) showed no survival benefit from
gemcitabine plus vinorelbine (MTS, 30 weeks) vs either single
agent (MST, 28 and 36 weeks, respectively) (Gridelli et al, 2003).
However, 20% of patients entered in the MILES trial were affected
by three, and 25% of patients by four or more associated diseases.
We wonder whether the greater toxicity, without any survival
advantage, elicited in the MILES trial by the combination as
compared with each of the components may be explained by this
observation. Another possible explanation for the apparent
discrepancy between MILES and SICOG 9909 studies may rely
on the slightly lower dosages used in that trial for the combination
(vinorelbine 25mgm
 2 plus gemcitabine 1000mgm
 2) than for
each single-agent arm (vinorelbine 30mgm
 2 and gemcitabine
1200mgm
 2). Although a dose–response relationship is
unproven in NSCLC, it is likely that at least an additive effect
may occur when full doses of both drugs are combined. As a
matter of fact, in both doublet arms of our study, but not in the
single-agent arms, RR was greater among patients who could
tolerate a dose escalation over the first three cycles. Noteworthy,
we were able to increase both gemcitabine and vinorelbine in
about a quarter of patients treated with GV. On the other hand,
vinorelbine in the MILES trial produced an unexpectedly long-
lasting MST, not only longer than the combination, but also
greater than that obtained in the previous ELVIS study (Elderly
Lung cancer Vinorelbine Italian Study Group, 1999), and
even superior to those (ranging from 30 to 32 weeks) reported
with this drug in three large randomised trials unrestricted to
elderly patients (Depierre et al, 1994; Le Chevalier et al, 1994;
Crawford et al, 1996).
As for the single agents of our trial, we would stress that MST
(5.1 months) and 1-year SR (30%) obtained in the GEM arm were
comparable to those achieved by gemcitabine either in the series
without an upper age limit for inclusion, or in trials specifically
designed for elderly patients. Indeed, an MST of 5.7 months and a
25% 1-year SR were reported for patients treated with GEM in a
randomised study comparing this drug to the best supportive care
(Anderson et al, 2000). In a phase II study restricted to patients
aged more than 70 years, an MST of 6.7 months was achieved with
GEM alone (Ricci et al, 2000). Moreover, Quoix (Quoix et al, 2003)
recently explored in elderly patients the activity of two different
schedules of gemcitabine (either 1000mgm
 2 for 3 consecutive
weeks every 4 weeks, or 1125mgm
 2 for 2 consecutive weeks every
3 weeks), reporting a MST of 5.1 and 6.8 months, respectively. In
the MILES trial, gemcitabine 1200mgm
 2 on days 1 and 8 every 3
weeks obtained a MST of 28 weeks, and a 28% 1-year SR (Gridelli
et al, 2003).
As for the PTX arm, MST (6.4 months) and 1-year SR (24%)
achieved in our study were comparable to those (6.8 months, and
35%, respectively) reported in a phase III trial comparing this drug
with supportive care alone (Ranson et al, 2000). Moreover, in a
large randomised study evaluating the addition of carboplatin to
PTX in NSCLC patients, the single-agent PTX treatment yielded in
the subset of elderly patients a MST of 5.0 months, with 1-year SR
of 31% (Bunn and Lilenbaum, 2003).
One of the secondary end points of this study was to assess
whether there was a substantial difference in safety between
the regimens utilised. In this regard, we can state that no
additional toxicity derived from the combination of two drugs in
comparison with a single agent. Among doublets, similar
proportions of patients treated with either GV or GT were affected
by side effects of any grade, and few episodes of grade 4
neutropenia and/or febrile neutropenia, as well as of severe
nonhaematologic toxicity, occurred in both arms. These findings
were likely a consequence of the tailored approach we have
used, applying very cautious rules for dose reduction/omission
in the presence of haematologic toxicity, escalating the cytotoxic
drugs only in the absence of relevant toxicity on previous
cycle, and discontinuing any chemotherapy in patients showing
no clear benefit from such treatment. This prudential approach
has been adopted in consideration of the unpredictable occurrence
in elderly subjects of side effects from cytotoxic drugs also in
the presence of apparently normal organ functions (Lichtman
et al, 1999; Aapro et al, 2000). As a matter of fact, the occurrence
of severe bone marrow toxicity was even lower in the present
trial than in our previous study (Frasci et al, 2000), in which
full doses of gemcitabine (1200mgm
 2) plus vinorelbine
(30mgm
 2) were administered from the beginning, while dose-
reduction rules during treatment were exactly the same.
Besides the PS of patients, we were unable to identify other
pre-treatment features significantly affecting the treatment com-
pliance in this study. Since the proportion of patients with poor
PS did not differ in this and in our previous trial, we may
argue that the pragmatic adaptation of treatment intensity
represents a good way to improve the tolerability of cytotoxic
drugs in elderly people.
In conclusion, this trial showed that survival of elderly advanced
NSCLC patients, carefully selected on the basis of their Charlson
score, may be prolonged using a non-cisplatin-based doublet, at
the price of acceptable side effects. The significantly greater
efficacy of doublets over a single agent was confirmed in the
multivariate analysis. GT combination was associated with the best
therapeutic index, and should be considered a reference regimen
for these patients. However, a poor performance status was
independently associated with a worse survival regardless of
treatment employed. Therefore, future trials exploring new regi-
mens should be restricted to patients with an ECOG PS p1.
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